Articles tagged "B cells"

2021 American Transplant Congress
Belatacept and Carfilzomib-based Treatment of Active Antibody-mediated Rejection in a Sensitized Nonhuman Primate Model
J. Kwun¹, R. Schmitz¹, M. Manook¹, Z. Fitch¹, D. Olaso¹, A. Choi¹, J. Yoon¹, Y. Bae¹, J. Lambris², S. Knechtle¹
¹Surgery, Duke University, Durham, NC, ²Pathology & Laboratory Medicine, University of Pennsylvania, Philadelphia, PA
*Purpose: One third of sensitized, HLA-incompatible transplant recipients experience antibody-mediated rejection (AMR) with limited effective treatment options. We tested a novel treatment strategy for AMR…
2021 American Transplant Congress
CD40 Blockade by the Fc-Silent Immunosuppressive Antibody Iscalimab Results in Diminished B Cell Activation and Differentiation and is Paralleled by Whole Blood Gene Expression Data
R. Kraaijeveld¹, M. W. van den Hoogen¹, A. E. de Weerd¹, E. Ferroro², G. Robert², U. Laessing², B. Haraldsson², J. S. Rush², C. C. Baan¹
¹Erasmus MC, Rotterdam, Netherlands, ²Novartis Pharmaceuticals AG, Basel, Switzerland
*Purpose: Blockade of costimulatory molecule CD40 by the Fc-silent immunosuppressive drug Iscalimab has shown to inhibit acute alloreactivity in non-human primates and is currently being…
2021 American Transplant Congress
TOLS are Novel Regulatory TLOs with A B Cell Signature
I. Rosales¹, Q. Yuan¹, C. Yang¹, P. Russell¹, J. Madsen¹, A. Alessandrini¹, R. Colvin¹, -. AA and RC²
¹Massachusetts General Hospital, Boston, MA, ²Co-Senior Authors, Boston, MA
*Purpose: Our previous studies suggest that a DBA/2 kidney graft is accepted by a MHC-fully mis-matched C57/BL6 recipient. Accepted renal allografts exhibited lymphoid like structures…
2021 American Transplant Congress
Contribution of T-bet Expressing CD27+ CD21- Activated Memory B Cells Poised for Plasma Cell Differentiation to Antibody-mediated Rejection of Kidney Transplants
K. Louis¹, E. Bailly¹, C. Macedo¹, B. Ramaswami¹, X. Gu¹, G. Chalasani¹, A. Zeevi¹, P. Randhawa¹, H. Singh², C. Lefaucheur³, D. Metes¹
¹Surgery, University of Pittsburgh, Pittsburgh, PA, ²Center for Systems immunology, Department of Immunology, University of Pittsburgh, Pittsburgh, PA, ³Human Immunology and Immunopathology, INSERM U976, Paris, France
*Purpose: Alloimmunity triggered by donor-specific antibodies (DSAs) and ensuing development of antibody-mediated rejection (ABMR) are detrimental to organ transplants. Yet, the cellular states underlying B…
2021 American Transplant Congress
Evaluation of Rituximab-abbs in Renal Transplant: A Case Series
A. Dao¹, B. Jimenez², A. Reyad¹, J. Guiteau¹, M. Madhrira³, N. Umezurike¹, S. Patel¹, S. Allam³
¹Transplant, Medical City Fort Worth, Fort Worth, TX, ²College of Pharmacy, University of North Texas, Fort Worth, TX, ³Tarrant Nephrology Associates, Premier Physicians Group Health, Fort Worth, TX
*Purpose: Biosimilars are FDA-approved alternatives to cost-prohibitive biologics, with no clinically meaningful differences in safety, purity, and potency. Rituximab-abbs, a biosimilar to rituximab, has labeled…
2021 American Transplant Congress
Intrarenal B-cell Activating Factor (BAFF) Levels are Increased in Transplant Glomerulopathy
S. Panzer, K. Swanson, G. Pandya, L. Hidalgo, S. Reese
University of Wisconsin Madison, Madison, WI
*Purpose: Transplant glomerulopathy (TG), a key feature of chronic active antibody-mediated rejection (caABMR), is associated with allograft failure. B-cell activating factor (BAFF) is a cytokine…
2021 American Transplant Congress
Selective Bcl-2 Inhibition for Induction of Mixed Chimerism and Renal Allograft Tolerance without Myelosupression
G. Lassiter¹, T. Hirose¹, H. Sasaki¹, D. Ma¹, T. Oura¹, A. Dehnadi¹, A. Cosimi¹, P. Cippa², T. Fehr³, T. Kawai¹
¹Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, ²Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland, ³Division of Nephrology, University of Zurich, Zurich, Switzerland
*Purpose: Immunologic tolerance of renal allograft has been achieved by induction of hematopoietic chimerism through donor bone marrow transplantation (DBMT). The myeloablative and genetic toxicity…
2021 American Transplant Congress
The Effect of Daratumumab (Dara, Humanized Anti-CD38 Monoclonal Antibody) on Immune Cells In Vitro and in a HLA-Sensitized Kidney Transplant Patient (HS KTx Pt) Desensitized (DES) with Dara
S. Ge¹, M. Chu¹, A. De Guzman¹, E. Ortiz¹, A. Vo², N. Ammerman², S. C. Jordan², M. Toyoda¹
¹Transplant Immunology Laboratory, Cedars Sinai Medical Center, Los Angeles, CA, ²Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA
*Purpose: Antibody-Mediated Rejection (ABMR), primarily mediated by B cells, plasma cells (PC) and antibodies (Ab), is an obstacle for successful transplantation in HS KTx Pts.…
2021 American Transplant Congress
Iguratimod Prevents Antibody-mediated Rejection by Regulating Germinal Center Formation and Antibody Production
H. Zhang, A. Chandraker, P. Sage, N. Murakami
Transplantation Research Center, Brigham and Women's Hospital, Boston, MA
*Purpose: Antibody-mediated rejection (ABMR) is a major cause of chronic renal allograft failure without effective treatment, and developing a novel therapy is an urgent need.…
2021 American Transplant Congress
Development of a Rat Model of Antibody-Mediated Rejection After Liver Transplantation
T. Tajima, K. Hata, J. Kusakabe, H. Miyauchi, S. Uemoto
Dept. of Surgery, Div. of HBP Surgery & Transplantation, Kyoto University Graduate School of Medicine, Kyoto, Japan
*Purpose: Antibody-mediated rejection (AMR) is a refractory rejection after donor-specific antibody (DSA)-positive or ABO blood-type incompatible liver transplantation (LT), due at least in part to…

1
2
3
…
30
Next Page »